Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2019-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '차바이오텍' covering the period from January 1, 2019, to March 31, 2019. It contains detailed corporate information, history, capital changes, and financial data structures typical of a formal quarterly financial filing. It is not an announcement or a certification, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-15 Korean
유상증자결정(종속회사의주요경영사항)(주주배정후실권주일반공모)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Cha Biotech regarding a capital increase (paid-in capital increase) for its subsidiary, CMG Pharmaceutical. It details the number of new shares, the purpose of the funds (facility and operating capital), the issuance method (shareholder allocation followed by general public offering), and the specific timeline for subscription and payment. This is a standard corporate announcement regarding capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2019-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special related parties, including specific transaction dates, methods (e.g., market purchases, changes in special relationship status), and the resulting changes in shareholding percentages. This document type is specifically designed for reporting significant ownership thresholds and does not fit into categories like 10-K, Earnings Release, or Investor Presentation. It is a formal regulatory disclosure.
2019-05-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often filed with the Financial Supervisory Service/DART) to report insider trading activities, specifically share acquisitions by an executive (Lee Il Han) of CHA Biotech. This falls under the 'Director's Dealing' category.
2019-05-03 Korean
기타경영사항(특허권취득)(자율공시)(인간 다능성 줄기세포 단일세포의 계대배양 방법 및 이를 이용한 형질전환 인간 다능성 줄기세포 제조 방법)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by Cha Biotech. It details the patent name, content, and utilization plan. Since it is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2019-04-22 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (Corporate Day). It provides details such as date, location, purpose, and contact information, and mentions that materials will be distributed at the event or available online. Since it is an announcement of an event rather than the presentation itself, and it does not fit into other specific categories, it is classified as a Regulatory Filing (RNS).
2019-04-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.